Etiology, Prevention, and Treatment of Hepatocellular Carcinoma(R21) | Apply Online

Opportunity Summary:

The Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (R21) opportunity (Funding Opportunity Number PA-08-244) is a National Institutes of Health (NIH) discretionary grant announcement led by the National Cancer Institute (NCI) in partnership with the National Institute on Alcohol Abuse and Alcoholism (NIAAA). Its central aim is to stimulate early-stage, exploratory research that can deepen understanding of hepatocellular carcinoma (HCC) and move the field toward better ways to prevent, detect, predict outcomes for, and treat this form of liver cancer. The announcement is explicitly oriented toward the basic biology of HCC and toward translational ideas that emerge from mechanistic work, rather than toward broad population-only research.

Scientifically, the FOA highlights several priority directions. First, it encourages studies on HCC etiology and the underlying etiologic mechanisms, meaning projects that examine causative factors and the biological pathways through which those factors drive malignant transformation in the liver. This can include molecular and cellular events that connect known risk exposures or liver injury states to carcinogenesis. Second, it invites the development of animal models for HCC, reflecting the need for improved in vivo systems that better mirror human disease initiation, progression, and response to interventions. Third, it seeks novel strategies to prevent HCC malignancy, which can range from blocking early carcinogenic steps to interrupting progression in high-risk settings, provided the work is grounded in biological mechanisms. Fourth, it supports development of therapeutic or diagnostic tools aimed at producing reliable prognostic indicators for HCC, such as biomarkers, assays, imaging approaches, or other technologies that can help predict disease course or treatment response. Fifth, it encourages therapeutic approaches designed to reduce morbidity and mortality from HCC in humans, including innovative treatment concepts, combinations, or modality development, again with a clear emphasis on mechanistic rationale and potential impact.

A key boundary in the announcement is what it will not fund: applications focused solely on population studies and epidemiology are not supported under this FOA. In practice, that means projects need to be anchored in biological questions, model systems, intervention development, or mechanistically informed diagnostics/therapeutics rather than being limited to observational incidence, prevalence, or risk-factor mapping without a strong experimental or mechanistic component. The overall expectation is that the proposed research advances core understanding of liver cancer biology or produces early evidence for new prevention or treatment directions.

In terms of award structure, this FOA uses the NIH R21 mechanism, which is typically intended for exploratory and developmental projects that may be higher risk but potentially high payoff. The listed award ceiling is $200,000 (as provided in the opportunity summary). The FOA also notes it is part of a coordinated set of related announcements with similar scientific scope: an R01 version (PA-08-243) for more mature research projects and a P01 program project version (PAR-08-245) for larger, multi-project efforts. This positioning signals that PA-08-244 is meant for earlier-stage ideas or proof-of-concept work that could later grow into larger R01- or program-level initiatives.

Administrative details indicate there is no cost sharing or matching requirement. Funding levels and the number of awards are not predetermined; awards are contingent on the availability of funds and on receiving a sufficient number of scientifically meritorious applications, so applicants should treat the program as competitive and dependent on annual appropriations and portfolio priorities. The opportunity was posted on August 19, 2008, created on December 5, 2008, and had an original and final closing date of September 7, 2011, with an archive date of October 8, 2011, meaning it is no longer open but remains useful as a reference for NIH priorities and for understanding how similar current liver cancer FOAs may be framed.

Eligibility is broad and includes many organizational types: for-profit organizations (including those other than small businesses), small businesses, nonprofit organizations with or without 501(c)(3) status, public and private institutions of higher education, and state governments. Additional eligible applicants also include units of local government, U.S. territories or possessions, eligible federal agencies, regional organizations, and non-U.S. entities (foreign organizations). This breadth reflects NIH’s interest in encouraging participation from academia, industry, nonprofits, and international groups capable of contributing meaningful advances in HCC biology, model development, diagnostics, prevention, or therapy.

The funding activity aligns with health-related research categories associated with multiple CFDA listings spanning alcohol research programs and cancer research areas, including cancer biology, cause and prevention, detection and diagnosis, and treatment. The NIAAA’s involvement signals particular interest in pathways linking alcohol-related liver disease and injury to HCC mechanisms and interventions, though the FOA is not limited to alcohol-related HCC and is framed broadly around liver cancer biology and clinical impact.

For applicants or readers seeking the full historical announcement text and formal NIH instructions, the FOA points to the NIH Grants Guide link (http://grants.nih.gov/grants/guide/pa-files/PA-08-244.html) and provides NIH Office of Extramural Research (OER) webmaster contact information for access or technical linking issues.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (R01)

Previous opportunity: Reducing Risk Behaviors by Promoting Positive Youth Development (R03)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PA 08 244

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PA 08 244) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PA 08 244", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.